The likely pathogenic mechanisms of multiple sclerosis (MS) provide a sound rationale for investigating the efficacy of drugs possessing immunosuppressive or immunomodulatory properties. With proven efficacy, safety and tolerability, interferon beta formulations and glatiramer acetate have become the mainstay of initial treatment for patients with relapsing forms of MS. More recently, natalizumab, a humanized monoclonal antibody (mAb) against the cellular adhesion molecule α4-integrin, has been employed for patients with an inadequate response or lack of tolerability to an alternate MS therapy, or as initial therapy for patients with severe disease. Various agents initially developed for oncological indications, either as chemotherapeutics or mAbs, may also have current or future uses in MS treatment. Mitoxantrone is currently the only chemotherapeutic agent approved for treatment of MS in the United States, while in parts of Europe azathioprine is approved and widely used for MS treatment. Other chemotherapeutics that have been tested in MS to date include cyclophosphamide, methotrexate, cladribine, and the mAbs alemtuzumab and rituximab. While there has been varying evidence of efficacy for these compounds, each appears to be associated with serious risks that require careful consideration and management. Given the risks that have been demonstrated for available chemotherapeutic agents and while long-term postmarketing safety data are still not available for those agents in development, it seems prudent to carefully assess the possible use of chemotherapeutics in the treatment of MS. A thorough risk-benefit analysis is becoming increasingly important in the assessment of therapeutic options for this disabling disease.
Arnason, B.G., Dayal, A., Qu, Z.X., Jensen, M.A., Genç, K. and Reder, A.T. ( 1996) Mechanisms of action of interferon-beta in multiple sclerosis . Springer Sem Immunopathol18: 125-148.
2.
Arnold, D.L., Campagnolo, D., Panitch, H., Bar-Or, A., Dunn, J., Freedman, M.S. et al. (2008) Glatiramer acetate after mitoxantrone induction improves MRI markers of lesion volume and permanent tissue injury in MS. J Neurol255: 1473-1478.
3.
Beutler, E., Sipe, J.C., Romine, J.S., Koziol, J.A., McMillan, R. and Zyroff, J. ( 1996) The treatment of chronic progressive multiple sclerosis with cladribine. Proc Natl Acad Sci U S A93: 1716-1720.
4.
CAMMS223 Trial Investigators, Coles, A.J., Compston, D.A., Selmaj, K.W., Lake, S.L., Moran, S., Margolin, D.H. et al. (2008 ) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis . N Engl J Med359: 1786-1801.
5.
Campath (alemtuzumab) US prescribing information. Last accessed 11 November 2009berlex.bayerhealthcare.com/html/products/pi/Campath_PI.pdf .
6.
Carrá, A., Onaha, P., Luetic, G., Burgos, M., Crespo, E., Deri, N. et al. (2008) Therapeutic outcome 3 years after switching of immunomodulatory therapies in patients with relapsing-remitting multiple sclerosis in Argentina. Eur J Neurol15: 386-393.
7.
Casetta, I., Iuliano, G. and Filippini, G. ( 2007) Azathioprine for multiple sclerosis. Cochrane Database Syst RevCD003982, DOI: 10.1002/ 14651858.CD003982.pub2.
8.
Chan, A., Weilbach, F.X., Toyka, K.V. and Gold, R. ( 2005) Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol139: 152-158.
9.
Clifford, D.B., De Luca, A., Simpson, D.M., Arendt, G., Giovannoni, G. and Nath, A.(2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol9: 438-446.
10.
Cohen, J.A., Imrey, P.B., Calabresi, P.A., Edwards, K.R., Eickenhorst, T., Felton, W.L. et al. (2009) Results of the Avonex Combination Trial (ACT) in relapsing-remitting MS. Neurology72: 535-541.
11.
Coles, A.J., Wing, M.G., Molyneux, P., Paolillo, A., Davie, C.M., Hale, G. et al. (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol46: 296-304.
12.
Coles, A.J., Cox, A., Le Page, E., Jones, J., Trip, S.A., Deans, J. et al. (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol253: 98-108.
13.
Comi, G., Filippi, M., Barkhof, F., Durelli, L., Edan, G., Fernández, O. et al. (2001a) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet357: 1576-1582.
14.
Comi, G., Filippi, M. and Wolinsky, J.S. and the European/Canadian Glatiramer Acetate Study Group. ( 2001b) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann Neurol49: 290-297.
15.
Comi, G., Cook, S., Giovannoni, G., Rammohan, K., Rieckmann, P., Sorensen, P.S. et al. (2009) Reductions in MRI activity in relapsing-remitting multiple sclerosis achieved with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. Mult Scler15(Suppl 2): S136, Abstract P469.
16.
Confavreux, C., Saddier, P., Grimaud, J., Moreau, T., Adeleine, P. and Aimard, G. ( 1996) Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology46: 1607-1612.
17.
Cook, S., Vermersch, P., Comi, G., Giovannoni, G., Rammohan, K., Rieckmann, P. et al. (2009) Safety and tolerability of cladribine tablets in relapsing-remitting multiple sclerosis during the 96-week, phase III, double-blind, placebo-controlled CLARITY study. Mult Scler15(Suppl 2): S21, Abstract 88.
18.
Cotte, S., von Ahsen, N., Kruse, N., Huber, B., Winkelmann, A., Zettl, U.K. et al. (2009) ABCtransporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain132: 2517-2530.
19.
Cyclophosphamide US prescribing information. Last accessed 11 November 2009, http://www.mims.com/Page.aspx?menuid=mng&CTRY=US&Name=Cyclophosphamide+Tablet.
20.
Dörr, J., Bitsch, A., Schmailzl, K.J., Chan, A., von Ahsen, N., Hummel, M. et al. (2009) Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology73: 991-993.
21.
Edan, G., Miller, D., Clanet, M., Confavreux, C., Lyon-Caen, O., Lubetzki, C. et al. (1997) Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry62: 112-118.
22.
Ellis, R. and Boggild, M.(2009) Therapy-related acute leukaemia with mitoxantrone: what is the risk and can we minimise it?Mult Scler15: 505-508.
23.
Etemadifar, M., Janghorbani, M. and Shaygannejad, V. ( 2007) Comparison of interferon beta products and azathioprine in the treatment of relapsing-remitting multiple sclerosis. J Neurol254: 1723-1728.
24.
Fernandez, O. ( 2007) Combination therapy in multiple sclerosis. J Neurol Sci259: 95-103.
25.
Filippi, M., Rovaris, M., Iannucci, G., Mennea, S., Sormani, M.P. and Comi, G. ( 2000a) Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology55: 1714-1718.
26.
Filippi, M., Rovaris, M., Rice, G.P., Sormani, M.P., Iannucci, G., Giacomotti, L. et al. (2000b) The effect of cladribine on T(1) ‘black hole’ changes in progressive MS. J Neurol Sci176: 42-44.
27.
Fleischmann, R.M. ( 2009) Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. Arthritis Rheum60: 3225-3228.
28.
Ghalie, R.G., Mauch, E., Edan, G., Hartung, H.P., Gonsette, R.E., Eisenmann, S. et al. (2002) A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler8: 441-445.
Giovannoni, G., Comi, G., Cook, S., Rammohan, K., Rieckmann, P., Sorensen, P.S. et al. (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med362: 416-426.
31.
Gladstone, D.E., Zamkoff, K.W., Krupp, L., Peyster, R., Sibony, P., Christodoulou, C. et al. (2006) High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis. Arch Neurol63: 1388-1393.
32.
Gold, R. ( 2008) Combination therapies in multiple sclerosis. J Neurol255(Suppl 1): 51-60.
33.
Gonsette, R.E. ( 2008) Oxidative stress and excitotoxicity: a therapeutic issue in multiple sclerosis. Mult Scler14: 22-34.
34.
Goodkin, D.E., Plencner, S., Palmer-Saxerud, J., Teetzen, M. and Hertsgaard, D. ( 1987) Cyclophosphamide in chronic progressive multiple sclerosis: maintenance vs nonmaintenance therapy. Arch Neurol44: 823-827.
35.
Gray, O., McDonnell, G.V. and Forbes, R.B. ( 2004) Methotrexate for multiple sclerosis. Cochrane Database Syst Rev2: CD003208.
36.
Gray, O.M., McDonnell, G.V. and Forbes, R.B. ( 2006) A systematic review of oral methotrexate for multiple sclerosis. Mult Scler12: 507-510.
37.
Hartung, H.P., Gonsette, R., König, N., Kwiecinski, H., Guseo, A., Morrissey, S.P. et al. (2002) Mitoxantrone in Multiple Sclerosis Study Group (MIMS). Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet360: 2018-2025.
38.
Hauser, S., Dawson, D., Lehrich, J., Beal, M.F., Kevy, S.V., Propper, R.D. et al. (1983) Intensive immunosuppression in progressive multiple sclerosis: a randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH. N Engl J Med308: 173-180.
39.
Hauser, S.L., Waubant, E., Arnold, D.L., Vollmer, T., Antel, J., Fox, R.J. et al. (2008) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med358: 676-688.
40.
Hawker, K., O’Connor, P., Freedman, M.S., Calabresi, P.A., Antel, J., Simon, J. et al. (2009) Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol66: 460-471.
41.
Hutchinson, M., Kappos, L., Calabresi, P.A., Confavreux, C., Giovannoni, G., Galetta, S.L. et al. (2009) The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol256: 405-415.
42.
Jacobs, L.D., Cookfair, D.L., Rudick, R.A., Herndon, R.M., Richert, J.R., Salazar, A.M. et al. (1996) The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol39: 285-294.
43.
Jeffery, D.R., Chepuri, N., Durden, D. and Burdette, J. ( 2005) A pilot trial of combination therapy with mitoxantrone and interferon beta-1b using monthly gadolinium-enhanced magnetic resonance imaging. Mult Scler11: 296-301.
44.
Johnson, K.P., Brooks, B.R., Cohen, J.A., Ford, C.C., Goldstein, J., Lisak, R.P. et al. (1995) The Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. Neurology45: 1268-1276.
45.
Kappos, L., Polman, C.H., Freedman, M.S., Edan, G., Hartung, H.P., Miller, D.H. et al. (2006) Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology67: 1242-1249.
46.
Kappos, L., Freedman, M.S., Polman, C.H., Edan, G., Hartung, H.P., Miller, D.H. et al. (2007) Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet370: 389-397.
47.
Khan, O.A., Zvartau-Hind, M., Caon, C., Din, M.U., Cochran, M., Lisak, D. et al. (2001) Effect of monthly intravenous cyclophosphamide in rapidly deteriorating multiple sclerosis patients resistant to conventional therapy. Mult Scler7: 185-188.
48.
Kieseier, B.C., Putzki, N., Bates, D., Hutchinson, M., Pace, A. and Hyde, R. ( 2009) Improvement in quality-of-life outcomes with natalizumab in multiple sclerosis patients with highly active disease. Neurology72(Suppl 3): A238.
49.
Kinkel, R.P., Kollman, C., O’Connor, P., Murray, T.J., Simon, J., Arnold, D. et al. (2006) IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology66: 678-684.
50.
Kopadze, T., Dehmel, T., Hartung, H.P., Stüve, O. and Kieseier, B.C. ( 2006) Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. Arch Neurol63: 1572-1578.
51.
Krapf, H., Morrissey, S.P., Zenker, O., Zwingers, T., Gonsette, R. and Hartung, H.P. for the MIMS Study Group. (2005) Effect of mitoxantrone on MRI in progressive MS: results of the MIMS trial . Neurology65: 690-695.
52.
Le Page, E., Leray, E., Taurin, G., Coustans, M., Chaperon, J., Morrissey, S.P. et al. (2008) Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry79: 52-56.
53.
Le Page, E. and Edan, G. ( 2009) Long-term experience with induction treatment regimens in multiple sclerosis. J Neurol Sci277(Suppl 1): S46-S49.
54.
Leustatin (cladribine) US prescribing information. Last accessed 11 November 2009, http://www.orthobiotech.com/orthobiotech/shared/OBI/PI/Leustatin_PI.pdf.
55.
Lhermitte, F., Marteau, R. and Roullet, E. ( 1984) Not so benign long-term immunosuppression in multiple sclerosis. Lancet1: 276-277.
56.
Likosky, W.H., Fireman, B., Elmore, R., Eno, G., Gale, K., Goode, G.B. et al. (1991) Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study. J Neurol Neurosurg Psychiatry54: 1055-1060.
57.
Linker, R. and Kieseier, B.C. ( 2008) Innovative therapy with monoclonal antibodies in multiple sclerosis. Ther Adv Neurol Disord1: 33-42.
58.
Markowitz, C.E. ( 2007) Interferon-beta: mechanism of action and dosing issues . Neurology68(24 Suppl 4): S8-S11.
59.
Marriott, J.J., Miyasaki, J.M., Gronseth, G. and O’Connor, P.W. ( 2010) Evidence Report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis. Neurology74: 1463-1470.
60.
Martinelli, V. ( 2009) Leukemia risk with Mitoxantrone for multiple sclerosis . American Academy of Neurology 61st Annual Meeting, Seattle, WA, 25 April-2 May 2009. Abstract LB3.001.
61.
Methotrexate US prescribing information. Last accessed 11 November 2009, http://www.mims.com/Page.aspx?menuid=mng&CTRY=US&Name=Methotrexate+Injection%2C+Solution.
62.
Millefiorini, E., Gasperini, C., Pozzilli, C., D’Andrea, F., Bastianello, S., Trojano, M. et al. (1997) Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome . J Neurol244: 153-159.
63.
Morrissey, S.P., Le Page, E. and Edan, G. ( 2005) Mitoxantrone in the treatment of multiple sclerosis. Int Mult Scler J12: 74-87.
64.
Neuhaus, O., Wiendl, H., Kieseier, B.C., Archelos, J.J., Hemmer, B., Stüve, O. et al. (2005) Multiple sclerosis: mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol168: 128-137.
65.
Neuhaus, O., Kieseier, B.C. and Hartung, H.P. ( 2006) Therapeutic role of mitoxantrone in multiple sclerosis . Pharmacol Ther109: 198-209.
66.
Noseworthy, J.H., Lucchinetti, C., Rodriguez, M. and Weinshenker, B.G. ( 2000) Multiple sclerosis. N Engl J Med343: 938-952.
67.
Novantrone (mitoxantrone) US prescribing information. Last accessed 9 November 2009, http://www.novantrone.com/assets/pdf/novantrone_prescribing_info.pdf.
68.
Paolillo, A., Coles, A.J., Molyneux, P.D., Gawne-Cain, M., MacManus, D., Barker, G.J. et al. (1999) Quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H. Neurology53: 751-757.
69.
Platten, M. and Steinman, L. ( 2005) Multiple sclerosis: trapped in deadly glue. Nat Med11: 252-253.
70.
Polman, C.H., O’Connor, P.W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D.H. et al. (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med354: 899-910.
71.
PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group ( 1998) Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet352: 1498-1504.
72.
Racke, M.K. ( 2008) The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr Opin Neurol21(Suppl 1): S9-S18.
73.
Racke, M.K., Lovett-Racke, A.E. and Karandikar, N.J.(2010) The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology74(Suppl 1): S25-S30.
74.
Rejdak, K., Petzold, A., Stelmasiak, Z. and Giovannoni, G. ( 2008) Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Mult Scler14: 59-66.
75.
Rice, G.P., Filippi, M. and Comi, G. ( 2000) Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology54: 1145-1155.
76.
Rieckmann, P., Comi, G., Cook, S., Giovannoni, G., Rammohan, K., Sorensen, P.S. et al. (2009) Effects of cladribine tablets on peripheral lymphocyte subtypes implicated in multiple sclerosis immunopathogenesis: surface marker analysis for a subset of patients from the 96-week, phase III, double-blind, placebo-controlled CLARITY study. Mult Scler15(Suppl 2): S248, Abstract P816.
77.
Rituximab (Marketed and Rituxan) Information ( 2006) US Food and Drug Administration Center for Drug Evaluation and Research, US Department of Health and Human Services : Rockville, MD.
78.
Romine, J.S., Sipe, J.C., Koziol, J.A., Zyroff, J. and Beutler, E. ( 1999) A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Physicians111: 35-44.
79.
Rudick, R.A., Stuart, W.H., Calabresi, P.A., Confavreux, C., Galetta, S.L., Radue, E.W. et al. (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med354: 911-923.
80.
Saven, A., Burian, C., Koziol, J.A. and Piro, L.D. ( 1998) Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood92: 1918-1926.
81.
Sipe, J.C., Romine, J.S., Koziol, J.A., McMillan, R., Zyroff, J. and Beutler, E. ( 1994) Cladribine in treatment of chronic progressive multiple sclerosis. Lancet344: 9-13.
82.
Sipe, J.C. ( 2005) Cladribine for multiple sclerosis: review and current status. Expert Rev Neurother5: 721-727.
83.
Smith, D. ( 2004) Preliminary analysis of a trial of pulse cyclophosphamide in IFN-beta-resistant active MS. J Neurol Sci223: 73-79.
84.
Smith, D.R., Weinstock-Guttman, B., Cohen, J.A., Wei, X., Gutmann, C., Bakshi, R. et al. (2005)
85.
A randomized, blinded trial of combination therapy with cyclophosphamide in patients with active MS on interferon-beta. Mult Scler11: 573-582.
86.
Soelberg-Sorensen, P., Comi, G., Cook, S., Giovannoni, G., Rammohan, K., Rieckmann, P. et al. (2009) Effects of cladribine tablets on haematological profiles in patients with relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. Mult Scler15(Suppl 2): S137, Abstract P472.
87.
The Canadian Cooperative Multiple Sclerosis Study Group ( 1991) The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet337: 441-446.
88.
The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group (1995) Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. Neurology45: 1277-1285.
89.
The International Multiple Sclerosis Genetics Consortium ( 2007) Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med357: 851-862.
90.
van Boxel-Dezaire, A.H., Hoff, S.C., van Oosten, B.W., Verweij, C.L., Dräger, A.M., Adèr, H.J. et al. (1999) Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol45: 695-703.
91.
van de Wyngaert, F.A., Beguin, C., D’Hooghe, M.B., Dooms, G., Lissoir, F., Carton, H. et al. (2001) A double-blind clinical trial of mitoxantrone versus
Vartanian, T. ( 2003) An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of interferon beta products in the treatment of multiple sclerosis. Clin Ther25: 105-118.
94.
Vermersch, P., Comi, G., Cook, S., Giovannoni, G., Rammohan, K., Rieckmann, P. et al. (2009) Early onset of effect of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, phase III, double-blind, placebo-controlled CLARITY study. Mult Scler15(Suppl 2): S249, Abstract P817.
95.
Vollmer, T., Panitch, H., Bar-Or, A., Dunn, J., Freedman, M.S., Gazda, S.K. et al. (2008) Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis. Mult Scler14: 663-670.
96.
Weiner, H.L. and Cohen, J.A. ( 2002) Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler8: 142-154.
97.
Weiner, H.L., Mackin, G.A., Orav, E.J., Hafler, D.A., Dawson, D.M., La Pierre, Y. et al. (1993) Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group. Neurology43: 910-918.
98.
Yates, C.R., Krynetski, E.Y., Loennechen, T., Fessing, M.Y., Tai, H.L., Pui, C.H. et al. (1997) Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance . Ann Intern Med126: 608-614.
99.
Yong, V.W., Chabot, S., Stuve, O. and Williams, G. ( 1998) Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology51: 682-689.
100.
Zaffaroni, M., Rizzo, A., Baldini, S.M., Ghezzi, A. and Comi, G. ( 2008) Induction and add-on therapy with mitoxantrone and interferon beta in multiple sclerosis. Neurol Sci29(Suppl 2): S230-S232.
101.
Zipoli, V., Portaccio, E., Hakiki, B., Siracusa, G., Sorbi, S. and Amato, M.P. ( 2008) Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. J Neurol Sci266: 25-30.
